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 Blockade of PDGF 
receptor signaling reduces 
myofibroblast number and 
attenuates renal fibrosis 
 Valerie S.   LeBleu 1 and  Raghu  Kalluri 1 , 2 , 3  
 Fibrosis can be considered as wound healing that never ceases, and 
activated fibroblasts (myofibroblasts) probably play a critical role 
in this unabated tissue repair process. In the setting of renal fibrosis, 
two central questions remain unanswered: Where do activated 
myofibroblasts come from; and what mechanism or mechanisms 
keep them activated? The study by Chen and colleagues addresses 
the role of platelet-derived growth factor receptor (PDGFR) signaling in 
the activation of myofibroblasts. 
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 Fibrosis can be considered as wound 
healing that never ceases. In the setting of 
tissue repair, myofi broblasts appear in 
conjunction with infl ammatory response 
to provide the required physical and bio-
chemical support to enable regeneration, 
upon which all repair activities come to a 
halt with the disappearance of activated 
myofi broblasts and infl ammation. In the 
kidney, acute injury is associated with 
such plastic response, whereas in the 
chronic injury setting, the resolution 
phase associated with such regenerative 
process is impaired, resulting in unabated 
repair that leads to what is referred to as 
fi brosis. Although many key questions 
remain unanswered with regard to the 
mechanism behind organ fi brosis, the 
kidney is offering an excellent model 
system to systematically probe them. Two 
central questions that remain are: Where 
do activated fi broblasts (myofi broblasts) 
come from; and what mechanism or 
mechanisms keep them activated? In 
the study by Chen and colleagues 1 (this 
issue), the role of platelet-derived growth 
factor receptor (PDGFR) signaling in 
the activation of myofibroblasts is 
addressed. 
 Chen and colleagues 1 demonstrate that 
altered PDGF – PDGFR signaling is associ-
ated with kidney fibrosis, and provide 
compelling evidence for the role of 
PDGFR signaling in myofi broblast activa-
tion. Although the total number of 
PDGFR  /    +   cells (presumably interstitial 
cells) was not quantifi ed in this study, the 
authors clearly demonstrate an increase in 
expression of specifi c components of the 
PDGF – PDGFR signaling axis in renal 
fi brosis, with a robust increase in PDGF-A 
through PDGF-D and PDGFR  and 
PDGFR  . Th e use of anti-PDGFR  (1E10) 
and anti-PDGFR  (2C5) antibodies from 
ImClone Systems reduces the observed 
increase in PDGF and PDGFR gene 
expression in mouse fi brotic kidney and 
subsequently reduces the activation of 
PDGFR  and PDGFR  . By this approach, 
a marked decrease in the number of 
  -smooth muscle actin-positive (  SMA   +   ) 
interstitial myofibroblasts and overall 
COL1A1 and COL3A1 gene expression is 
noted. Th e authors suggest that impaired 
macrophage recruitment due to dimin-
ished PDGFR  /  signaling with the use 
of anti-PDGFR  /  antibodies, as well as 
imatinib mesylate (which also targets 
PDGFR  signaling), improves renal fi bro-
sis. Th is study by Chen and colleagues 1 is 
supported by published fi ndings of Wang 
and colleagues 2 which showed that imat-
inib mesylate might reduce renal fi brosis 
in unilateral ureteric obstruction in mice, 
and also by the studies by Lassila and col-
leagues 3 using mice with diabetic neph-
ropathy. Together these studies raise the 
interesting possibility that targeting 
PDGFR signaling might off er new thera-
peutic avenues for renal fi brosis, perhaps 
by reducing macrophage infi ltration. 
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 Many different sources of activated 
fi broblasts / myofi broblasts / mesenchymal 
cells in the setting of renal fi brosis have 
been proposed ( Figure 1 ), and in some 
cases mice that allow lineage tracing have 
also been used. 4 – 6 Nevertheless, the func-
tional role of myofibroblasts and their 
origin are still largely unknown. In this 
regard, the study by Chen and colleagues 1 
does not off er any new insights. A series 
of assumptions were made to support the 
notion that myofi broblasts emerge mostly 
from pericyte diff erentiation, but compel-
ling genetic, cell-biology, and biochemical 
data are lacking. 
 What is a pericyte? Comprehensive 
reviews have summarized fi ndings from 
electron microscopy imaging, genetic 
studies, expression profi le analyses, and 
immunolabeling experiments with the 
hope of providing a clear defi nition. 7,8 Th e 
term  ‘ pericyte ’ is oft en applied to those 
distinct cells with extended cytoplasmic 
processes that embrace the capillary base-
ment membrane on the abluminal side of 
the microvessels. The term  ‘ vascular 
smooth muscle cell ’ (VSMC) is applied to 
morphologically similar cells associated 
with larger blood vessels, perhaps with 
higher contractile properties and special-
ized blood-flow-regulating functions. 
Nevertheless, some ambiguity remains as 
to the diff erence between these two terms. 
The expression of markers including 
  -SMA, desmin, PDGFR  , and neuron-
glial 2 (NG2) varies in pericytes and 
VSMCs, depending on the vessel type, 
organ type, and specifi c pathological insult 
in a given tissue. 7,8 PDGFR  and NG2 were 
fi rst described in association with micro-
vessels of the brain, but their expression in 
other vascular beds may greatly diff er. 
 Th e tyrosine kinase receptor PDGFR  , 
the focus of the study by Chen and col-
leagues, 1 is expressed by fi broblasts, astro-
cytes, mesangial cells, endothelial cells, 
macrophages, and cancer cells. 1,9 – 12 Simi-
larly,   SMA is expressed by myofi broblasts 
and some VSMCs. 8,13 The difficulty in 
defi ning a specifi c pericyte marker under-
scores the challenge the community faces 
in identifying the origin of pericytes  and 
in identifying them as the origin of other 
cell types. Th e use of transgenic mice with 
broad specifi city, such as ColI-GFP trans-
genic mice (expressing green fl uorescent 
protein under the collagen I promoter), to 
supplement fate-mapping strategies off ers 
ambiguous answers with regard to the 
contribution of pericytes to the emergence 
of myofi broblasts. 6,14 Nevertheless, recent 
studies 2,3 and the one by Chen  et al. 1 iden-
tify new functional roles for PDGFR    +  
cells in renal fi brosis, in addition to their 
putative roles in maintaining vessel struc-
tural integrity and regulating blood fl ow. 
 The idea of  ‘ pericyte – myofibroblast 
transition ’ is intriguing; however, evidence 
for this notion does not exist in the study 
by Chen  et al. 1 Th e fact remains that one 
cannot assume that   SMA is not expressed 
in VSMCs / pericytes in the adult kidney 
(a vast body of literature does not support 
this notion) and that collagen I-express-
ing cells in the fi brotic kidney are exclu-
sively pericyte-derived. The more 
plausible explanation is that PDGFR    +  
cells in the kidney are of diverse cell types, 
and during fi brosis, PDGFR    +   cells of 
many diff erent origins probably contrib-
ute to the pathogenesis. Despite the pan-
specific nature of PDGFR   +   cells in 
fi brosis, Chen and colleagues 1 provide 
elegant and compelling evidence for the 
role of PDGFR signaling in this setting. 
Although more studies are required, there 
is no doubt that Chen and colleagues 1 
bring more attention to the role of the 
PDGFR signaling axis in renal fi brosis, 
and with many agents already available to 
target this pathway, exciting therapeutic 
possibilities can be explored for this dev-
astating disease. 
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 Figure 1  |  Proposed sources of myofibroblasts in kidney fibrosis. Activated fibroblasts, 
or myofibroblasts (center), can originate from proliferation of resident fibroblasts, epithelial-
to-mesenchymal transition (EMT), endothelial-to-mesenchymal transition (EndMT), and pericyte 
shedding, as well as from the bone marrow (BM). The origin(s) and mechanism(s) of activation may 
be multiple, dynamic, and functionally synergistic in renal fibrosis. 
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